cisplatin
Showing 51 - 75 of 1,923
Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic
Recruiting
- Untreated Resectable Pancreatic Adenocarcinoma
- +2 more
- Paclitaxel protein bound
- +3 more
-
Scottsdale, ArizonaHonorHealth Research Institute
May 10, 2022
Non-Squamous Non-Small Cell Lung Carcinoma, Stage I NSCLC, Stage IA Non-Small Cell Lung Carcinoma Trial in Abington,
Active, not recruiting
- Non-Squamous Non-Small Cell Lung Carcinoma
- +7 more
- Nivolumab
- +3 more
-
Abington, Pennsylvania
- +1 more
Sep 14, 2022
Immunotherapy;Envafolimab; Esophageal Cancer Trial (Envafolimab, Abraxane, Cisplatin)
Not yet recruiting
- Immunotherapy;Envafolimab; Esophageal Cancer
- Envafolimab
- +2 more
- (no location specified)
Apr 24, 2023
Incidental Gallbladder Carcinoma, Biliary Tract Cancer Trial in Frankfurt (Gemcitabine, Cisplatin, Oncologically radical
Recruiting
- Incidental Gallbladder Carcinoma
- Biliary Tract Cancer
- Gemcitabine
- +3 more
-
Frankfurt, GermanyKrankenhaus Nordwest gGmbH
Sep 7, 2022
Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Larynx Cancer Trial in United Kingdom (AZD1775,
Completed
- Hypopharynx Squamous Cell Carcinoma
- +2 more
- AZD1775
- +2 more
-
Birmingham, West Midlands, United Kingdom
- +5 more
Nov 9, 2022
Urothelial Carcinoma, Locally Advanced, Unresectable Trial in United States (Atezolizumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Urothelial Carcinoma
- +2 more
- Atezolizumab
- +2 more
-
Chicago, Illinois
- +8 more
Dec 23, 2022
Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma Resectable Trial in Scottsdale (Ascorbic Acid, Paclitaxel
Completed
- Pancreatic Cancer
- +4 more
- Ascorbic Acid
- +3 more
-
Scottsdale, ArizonaHonorHealth Research Institute
Feb 10, 2022
Urothelial Carcinoma Trial in United States (Gemcitabine, Cisplatin, Ipilimumab)
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma Trial (pembrolizumab, cisplatin, 5-FU)
Completed
- Gastric Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma
- pembrolizumab
- +3 more
- (no location specified)
Jul 13, 2022
SCCHN, Squamous Cell Carcinoma Trial in Birmingham (Cisplatin)
Recruiting
- SCCHN
- Squamous Cell Carcinoma
- Cisplatin
-
Birmingham, AlabamaUniversity of Alabama at Birmingham
Jan 5, 2023
Esophageal Squamous Cell Carcinoma Trial in Nanjing (Carrelizumab, Paclitaxel injection, Cisplatin)
Enrolling by invitation
- Esophageal Squamous Cell Carcinoma
- Carrelizumab
- +3 more
-
Nanjing, ChinaThe First Affiliated Hospital of Nanjing Medical University
Sep 19, 2023
Adenocarcinoma, Pancreatic Tumors, Tumor, Glandular Trial in Baltimore (Nab-paclitaxel, Gemcitabine, Capecitabine)
Recruiting
- Adenocarcinoma
- +9 more
- Nab-paclitaxel
- +4 more
-
Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
Mar 15, 2022
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma Trial in United States (Atezolizumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Bladder Cancer
- +2 more
- Atezolizumab
- +2 more
-
Hartford, Connecticut
- +10 more
Nov 23, 2022
Cervical Carcinoma Trial in La Jolla (Intensity Modulated Radiation Therapy (IMRT), Cisplatin, Gemcitabine)
Completed
- Cervical Carcinoma
- Intensity Modulated Radiation Therapy (IMRT)
- +2 more
-
La Jolla, CaliforniaMoores UC San Diego Cancer Center
Feb 16, 2022
Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)
Not yet recruiting
- Diffuse Large B-cell Lymphoma
- Polatuzumab vedotin (PV)
- +6 more
-
Chapel Hill, North CarolinaLineberger Comprehensive Cancer Center
Aug 9, 2022
Urinary Bladder Tumors Trial in San Antonio (AGEN1884, AGEN2034, Cisplatin)
Active, not recruiting
- Urinary Bladder Neoplasms
- AGEN1884
- +3 more
-
San Antonio, TexasMays Cancer Center
Mar 11, 2022
Head and Neck Squamous Cell Carcinoma Trial in Tours (Docetaxel, Cisplatin, Fluorouracil)
Recruiting
- Head and Neck Squamous Cell Carcinoma
- Docetaxel
- +3 more
-
Tours, FranceHôpital Bretonneau, Service CORad Pôle Henry S Kaplan
Mar 10, 2022
Esophageal Squamous Cell Carcinoma Trial in Beijing (nab-paclitaxel, Cisplatin, Capecitabine)
Recruiting
- Esophageal Squamous Cell Carcinoma
- nab-paclitaxel
- +2 more
-
Beijing, ChinaNational Cancer Center/Cancer Hospital, Chinese Academy of Medic
Mar 13, 2022
Resectable Cholangiocarcinoma, Stage IB Intrahepatic Cholangiocarcinoma AJCC v8, Stage II Intrahepatic Cholangiocarcinoma AJCC
Active, not recruiting
- Resectable Cholangiocarcinoma
- +5 more
- Cisplatin
- +2 more
-
Atlanta, Georgia
- +6 more
Oct 5, 2022
Cervical Cancer Trial in Providence (Nivolumab induction, Cisplatin, Radiation)
Terminated
- Cervical Cancer
- Nivolumab induction
- +4 more
-
Providence, Rhode Island
- +1 more
Mar 30, 2022
Esophageal Carcinoma, Neoadjuvant Therapy Trial (Toripalimab, Anlotinib HCl, Albumin paclitaxel)
Not yet recruiting
- Esophageal Carcinoma
- Neoadjuvant Therapy
- Toripalimab
- +3 more
- (no location specified)
Aug 16, 2023
Biliary Tract Carcinoma Trial in China (Pembrolizumab, Gemcitabine, Cisplatin)
Active, not recruiting
- Biliary Tract Carcinoma
- Pembrolizumab
- +3 more
-
Hefei, Anhui, China
- +21 more
Aug 16, 2022
Urothelial Carcinoma of the Urinary Bladder Trial in New York (Cabazitaxel, Gemcitabine, Cisplatin)
Recruiting
- Urothelial Carcinoma of the Urinary Bladder
- Cabazitaxel
- +2 more
-
New York, New YorkColumbia University Medical Center- HIP
Feb 3, 2022
Locally Recurrent/Metastatic Triple Negative Breast Cancer Trial in United States (radiation, drug, procedure)
Recruiting
- Locally Recurrent/Metastatic Triple Negative Breast Cancer
- external beam radiation therapy
- +2 more
-
Basking Ridge, New Jersey
- +6 more
Aug 8, 2022